Ohio SB198 prohibits drug manufacturers from limiting reimbursements to 340B covered entities.
Ohio SB198 amends the state's insurance laws to prohibit drug manufacturers from restricting or limiting the acquisition of 340B drugs by 340B covered entities. This includes preventing manufacturers from requiring 340B grantees to submit claims or utilization data unless mandated by the U.S. Department of Health and Human Services. Violations of these provisions can result in civil penalties. The bill also repeals existing sections 3902.50, 3902.70, and 3902.72 of the Revised Code and enacts new section 3902.72 to implement these changes.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.